🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "major milestone" in the battle against increasingly resistant strains of the bacteria, according to scientists.

A Worldwide Challenge

Gonorrhoea infections are escalating around the world, with data suggesting in excess of 82 million instances per year. Especially elevated rates are seen in the African continent and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an critical and opportune step in the reality of rising global incidence, increasing antimicrobial resistance and the extremely scarce available drugs currently available.”

Medical experts are particularly alarmed about the rise in treatment-resistant strains. The global health body has classified it as a "critical concern". A tracking program found that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Gain Authorization

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Researchers believe that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, gained clearance in close succession. This medication, which is also used to treat urinary tract infections, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm Innoviva to bring it to fruition.

“This authorization represents a significant shift in the therapy of multidrug-resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Research Study Data and Worldwide Availability

As per findings released by a major medical journal, the new drug eradicated over nine in ten of uncomplicated infections. This places it at an comparable level with the existing first-line therapy, which uses an injection and a pill. The research involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, the non-profit has the authority to license and sell the drug in a wide range of developing nations.

Doctors treating patients have expressed hope. Access to a single-dose, oral treatment of this kind is described as a "revolutionary step" for managing the epidemic. This is considered essential to reduce the burden of the disease for patients and to prevent the spread of extremely resistant gonorrhoea around the world.